{"pmid":32231349,"title":"Chloroquine in COVID-19: the evidence.","text":["Chloroquine in COVID-19: the evidence.","To the Editor The Coronavirus disease 2019 (COVID-19) has been declared as a pandemic by World Health Organisation (WHO). The global mortality has increased, especially in countries like Italy and Iran. With the increasing morbidity and mortality, search for a cure has been the global demand.","Monaldi Arch Chest Dis","Gupta, Nitesh","Agrawal, Sumita","Ish, Pranav","32231349"],"abstract":["To the Editor The Coronavirus disease 2019 (COVID-19) has been declared as a pandemic by World Health Organisation (WHO). The global mortality has increased, especially in countries like Italy and Iran. With the increasing morbidity and mortality, search for a cure has been the global demand."],"journal":"Monaldi Arch Chest Dis","authors":["Gupta, Nitesh","Agrawal, Sumita","Ish, Pranav"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32231349","week":"202014|Mar 30 - Apr 05","doi":"10.4081/monaldi.2020.1290","source":"PubMed","locations":["Italy","Iran"],"countries":["Italy","Iran, Islamic Republic of"],"countries_codes":["ITA|Italy","IRN|Iran, Islamic Republic of"],"topics":["Treatment"],"weight":1,"_version_":1662899337684844544,"score":7.3910046,"similar":[{"pmid":32220020,"title":"What dermatologists could do to cope with the novel coronavirus (SARS-CoV-2): a dermatologist's perspective from China.","text":["What dermatologists could do to cope with the novel coronavirus (SARS-CoV-2): a dermatologist's perspective from China.","Coronavirus disease, first emerged in Wuhan, China, rapidly spread all over the country since December 2019[1]. Up to now, the epidemic situation in China remains stable, while the global march of the virus is seemingly unstoppable, especially in South Korea, Iran, and Italy[2]. Here, we reported what dermatologists could do to cope with novel coronavirus from a Chinese dermatologist's perspective.","J Eur Acad Dermatol Venereol","Zhang, Hanlin","Tang, Keyun","Fang, Rouyu","Sun, Qiuning","32220020"],"abstract":["Coronavirus disease, first emerged in Wuhan, China, rapidly spread all over the country since December 2019[1]. Up to now, the epidemic situation in China remains stable, while the global march of the virus is seemingly unstoppable, especially in South Korea, Iran, and Italy[2]. Here, we reported what dermatologists could do to cope with novel coronavirus from a Chinese dermatologist's perspective."],"journal":"J Eur Acad Dermatol Venereol","authors":["Zhang, Hanlin","Tang, Keyun","Fang, Rouyu","Sun, Qiuning"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32220020","week":"202013|Mar 23 - Mar 29","doi":"10.1111/jdv.16389","source":"PubMed","locations":["China","Wuhan","Iran","South Korea","Chinese"],"countries":["China","Korea, Republic of","Iran, Islamic Republic of"],"countries_codes":["CHN|China","KOR|Korea, Republic of","IRN|Iran, Islamic Republic of"],"topics":["Prevention"],"weight":1,"_version_":1662540582039322625,"score":82.75899},{"pmid":32221057,"title":"Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.","text":["Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.","A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed.","Indian J Ophthalmol","Shetty, Rohit","Ghosh, Arkasubhra","Honavar, Santosh G","Khamar, Pooja","Sethu, Swaminathan","32221057"],"abstract":["A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed."],"journal":"Indian J Ophthalmol","authors":["Shetty, Rohit","Ghosh, Arkasubhra","Honavar, Santosh G","Khamar, Pooja","Sethu, Swaminathan"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32221057","week":"202014|Mar 30 - Apr 05","doi":"10.4103/ijo.IJO_639_20","keywords":["COVID-19","SARS-CoV-2","prophylaxis","therapy"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662624089112576001,"score":77.18385},{"pmid":32218915,"pmcid":"PMC7097833","title":"National Institute for the Infectious Diseases \"L. Spallanzani\", IRCCS. Recommendations for COVID-19 clinical management.","text":["National Institute for the Infectious Diseases \"L. Spallanzani\", IRCCS. Recommendations for COVID-19 clinical management.","On January 9 2020, the World Health Organization (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a disease (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The \"L. Spallanzani\" National Institute for the Infectious Diseases, IRCCS, Rome, Italy, has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; they should be considered as expert opinions, which may be modified according to newly produced literature data.","Infect Dis Rep","Nicastri, Emanuele","Petrosillo, Nicola","Bartoli, Tommaso Ascoli","Lepore, Luciana","Mondi, Annalisa","Palmieri, Fabrizio","D'Offizi, Gianpiero","Marchioni, Luisa","Murachelli, Silvia","Ippolito, Giuseppe","Antinori, Andrea","32218915"],"abstract":["On January 9 2020, the World Health Organization (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a disease (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The \"L. Spallanzani\" National Institute for the Infectious Diseases, IRCCS, Rome, Italy, has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; they should be considered as expert opinions, which may be modified according to newly produced literature data."],"journal":"Infect Dis Rep","authors":["Nicastri, Emanuele","Petrosillo, Nicola","Bartoli, Tommaso Ascoli","Lepore, Luciana","Mondi, Annalisa","Palmieri, Fabrizio","D'Offizi, Gianpiero","Marchioni, Luisa","Murachelli, Silvia","Ippolito, Giuseppe","Antinori, Andrea"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32218915","week":"202013|Mar 23 - Mar 29","doi":"10.4081/idr.2020.8543","keywords":["COVID-19","SARS-CoV-2","Treatment"],"source":"PubMed","locations":["China","Italian","Italy"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"topics":["Treatment"],"weight":1,"_version_":1662540582040371200,"score":76.79516},{"pmid":32199877,"title":"Global epidemiology of coronavirus disease 2019: disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status.","text":["Global epidemiology of coronavirus disease 2019: disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status.","It has been 2 months since the first case of coronavirus disease 2019 (COVID-19) was reported in Wuhan. So far, COVID-19 has affected 84,503 patients in 57 countries/territories and caused 2,924 deaths in nine countries. However, the epidemiology data differ across countries. Although China had higher morbidity and mortality than other sites, the number of new cases per day in China is lesser than that outside of China since February 26, 2020. The incidence ranged from 61.4 per 1,000,000 people in Republic of Korea to 0.0002 per 1,000,000 people in India. The daily cumulative index (DCI) of COVID-19 (cumulative cases/no. of days between the first reported case and February 29, 2020) was greatest in China (1,320.85 per day), followed by Republic of Korea (78.78 per day), Iran (43.11 per day), and Italy (30.62 per day). However, the DCI in other countries/territories were less than 10 per day. Several effective measures including restricting travel from China, controlling the distribution of masks, extensive investigation of COVID-19 spread, and at once daily press conference by government to inform and educate people were aggressively conducted in Taiwan. This is probably the reason why there was only 39 cases (as of February 29, 2020) with a DCI of 1 case per day in Taiwan, which was much lower than that of nearby countries, such as Republic of Korea and Japan. Additionally, the incidence and mortality were correlated with DCI. However, further study and continued monitoring are needed to better understand the underlying mechanism of COVID-19.","Int J Antimicrob Agents","Lai, Chih-Cheng","Wang, Cheng-Yi","Wang, Ya-Hui","Hsueh, Shun-Chung","Ko, Wen-Chien","Hsueh, Po-Ren","32199877"],"abstract":["It has been 2 months since the first case of coronavirus disease 2019 (COVID-19) was reported in Wuhan. So far, COVID-19 has affected 84,503 patients in 57 countries/territories and caused 2,924 deaths in nine countries. However, the epidemiology data differ across countries. Although China had higher morbidity and mortality than other sites, the number of new cases per day in China is lesser than that outside of China since February 26, 2020. The incidence ranged from 61.4 per 1,000,000 people in Republic of Korea to 0.0002 per 1,000,000 people in India. The daily cumulative index (DCI) of COVID-19 (cumulative cases/no. of days between the first reported case and February 29, 2020) was greatest in China (1,320.85 per day), followed by Republic of Korea (78.78 per day), Iran (43.11 per day), and Italy (30.62 per day). However, the DCI in other countries/territories were less than 10 per day. Several effective measures including restricting travel from China, controlling the distribution of masks, extensive investigation of COVID-19 spread, and at once daily press conference by government to inform and educate people were aggressively conducted in Taiwan. This is probably the reason why there was only 39 cases (as of February 29, 2020) with a DCI of 1 case per day in Taiwan, which was much lower than that of nearby countries, such as Republic of Korea and Japan. Additionally, the incidence and mortality were correlated with DCI. However, further study and continued monitoring are needed to better understand the underlying mechanism of COVID-19."],"journal":"Int J Antimicrob Agents","authors":["Lai, Chih-Cheng","Wang, Cheng-Yi","Wang, Ya-Hui","Hsueh, Shun-Chung","Ko, Wen-Chien","Hsueh, Po-Ren"],"date":"2020-03-23T11:00:00Z","year":2020,"_id":"32199877","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.ijantimicag.2020.105946","keywords":["Coronavirus disease 2019","Country healthcare resources","Daily cumulative index","Disease incidence","Mortality"],"source":"PubMed","locations":["South Korea","Japan","China","Iran","Wuhan","Italy","India"],"countries":["Italy","China","India","Korea, Republic of","Iran, Islamic Republic of","Japan"],"countries_codes":["ITA|Italy","CHN|China","IND|India","KOR|Korea, Republic of","IRN|Iran, Islamic Republic of","JPN|Japan"],"topics":["Mechanism"],"weight":1,"_version_":1662334543282044928,"score":73.21493},{"pmid":32231348,"title":"Emerging prophylaxis strategies against COVID-19.","text":["Emerging prophylaxis strategies against COVID-19.","The Novel corona virus 2019 which started as an outbreak in China in December 2019 has rapidly spread all over the world, such that on 11th March 2020 WHO declared this disease as pandemic. The emergency that the world faces today demands that we develop urgent and effective measures to protect people at high risk of transmission. WHO has accelerated research in diagnostics, vaccines and therapeutics for this novel coronavirus.","Monaldi Arch Chest Dis","Agrawal, Sumita","Goel, Akhil Dhanesh","Gupta, Nitesh","32231348"],"abstract":["The Novel corona virus 2019 which started as an outbreak in China in December 2019 has rapidly spread all over the world, such that on 11th March 2020 WHO declared this disease as pandemic. The emergency that the world faces today demands that we develop urgent and effective measures to protect people at high risk of transmission. WHO has accelerated research in diagnostics, vaccines and therapeutics for this novel coronavirus."],"journal":"Monaldi Arch Chest Dis","authors":["Agrawal, Sumita","Goel, Akhil Dhanesh","Gupta, Nitesh"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32231348","week":"202014|Mar 30 - Apr 05","doi":"10.4081/monaldi.2020.1289","source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1662899337683795968,"score":65.97293}]}